Discount Agreement for Natalizumab
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Natalizumab in der Darreichungsform Konz.z.Herst.e.Inf.-Lsg. , ATC L04AG03
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
50 / 100
Risk factors
No estimated value or volume commitment means the financial opportunity is uncertain. Discount agreements may result in...
Contracts can be automatically terminated if other discount agreements (formal tender) come into effect. This introduce...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Nov 2027
- Provision of pharmaceutical products containing the active substance Natalizumab in the dosage form 'Konz.z.Herst.e.Inf.-Lsg.' (concentrate for solution for infusion).
- Non-exclusive discount agreements under § 130a Abs. 8 SGB V with AOK Bayern.
Show full summary
This is an open-house model for non-exclusive discount agreements (Rabattverträge) for the active substance Natalizumab (ATC L04AG03) in the dosage form 'Konz.z.Herst.e.Inf.-Lsg.' (concentrate for solution for infusion). The AOK Bayern intends to conclude identical, non-negotiable discount agreements with all interested pharmaceutical companies that meet the eligibility criteria. The procedure is not subject to procurement law and does not involve a selection. Contracts can be concluded at any time until 03.10.2027, with earliest start on 01.12.2025 and end on 30.11.2027. There is one lot covering all pharmaceutical products with the specified substance. No estimated value is provided.
Risks
No estimated value or volume commitment means the financial opportunity is uncertain. Discount agreements may result in...
Contracts can be automatically terminated if other discount agreements (formal tender) come into effect. This introduce...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies (pharmazeutische Unternehmen) are eligible to participate.
Administrative
- Submission of a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
- Submission of signed contract and annex listing the pharmaceutical products.
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Discount Agreement for Natalizumab
Non-exclusive discount agreements for the active substance Natalizumab in the specified dosage form, ATC L04AG03. Contracts are open to all eligible pharmaceutical companies.
Location
Duration
Category
Award Criteria
Deadline
Award details
No award criteria
all eligible companies are accepted on identical terms (open-house model).
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Natalizumab in der Darreichungsform Konz.z.Herst.e.Inf.-Lsg. , ATC L04AG03
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 13 Oct 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 673381-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
50 / 100
Risk factors
No estimated value or volume commitment means the financial opportunity is uncertain. Discount agreements may result in...
Contracts can be automatically terminated if other discount agreements (formal tender) come into effect. This introduce...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications